127 results
6-K
EX-99.1
GLPG
Galapagos NV
16 May 24
Current report (foreign)
8:11am
contained herein are based on management’s current expectations and beliefs and speak only as of the date hereof, and Galapagos makes no commitment
6-K
EX-99.1
GLPG
Galapagos NV
8 Apr 24
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
9:27am
on management’s current expectations and beliefs and speak only as of the date hereof, and Galapagos makes no commitment to update or publicly release
6-K
EX-99.5
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
performance commitment. Payments and company involvement are contractually defined by phase. At the outset, Management makes a estimate of the duration … supported by the fact that we concluded that there is only one results commitment remains related to filgotinib.
Identification of the result obligation
6-K
EX-99.14
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
included a commitment to make a proposal to the general meeting to issue the ‘Subsequent Gilead Warrant B’ that would enable Gilead Therapeutics to further … included a commitment to make a proposal to the shareholders’ meeting to authorize the Board of Directors to increase the share capital of the Company
6-K
EX-99.2
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
report Our Sustainability Commitment – Forward, Sustainably 82 Our Ambition 83 Our Sustainability Governance 84 Our Double Materiality Assessment 84 … future challenges.
Sustainability report Our commitment to society: Forward, Sustainably Pioneering science to transform patient outcomes
6-K
EX-99.15
1uy05mfmev4520 o0ur4
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.9
9pvwf4 mm9ldb6amg
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.4
hba9w6lu0u43gb1 2b
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.3
9h5ejdmn729e8q2eg0ip
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.1
mt2rb lyei
16 Feb 24
Galapagos presents at EBMT-EHA annual meeting 2024
6:00am
6-K
EX-99.1
8qnvs7
6 Feb 24
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
6:00am
6-K
EX-99.1
trjuhnn3j7nxcz95r
4 Jan 24
Current report (foreign)
5:32pm
6-K
EX-99.1
aj4dih35m24hn
4 Jan 24
Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology
4:07pm
6-K
EX-99.1
g7sejp5dl9mo
4 Jan 24
Galapagos signs agreement to transfer Jyseleca® business to Alfasigma
4:05pm
6-K
EX-99.1
m74ine4ulkdx 6sy
12 Dec 23
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
7:02am
6-K
EX-99.1
76umsl5kymnp xyc
12 Dec 23
Current report (foreign)
6:00am
S-8
EX-4.1
8151hxrz
4 Dec 23
Registration of securities for employees
5:16pm
6-K
EX-99.1
jpg0mbwc4gfipg68fegk
2 Nov 23
Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma
7:15am
6-K
EX-99.1
hpsl4tqgme93pdc6
20 Sep 23
Galapagos appoints Simon Sturge to its Board of Directors
6:00am